The Lancet Diabetes & Endocrinology
Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis
Trial in 30,787 peopleInterventions
Meta-analysis, randomised, placebo-controlled
- Semaglutide
- GLP-1 and incretin signalling
- Atherosclerotic cardiovascular disease
- Cardiovascular disease
- Chronic kidney disease
- Humans
The paper
KfH Kidney Center; UNSW Sydney
The Lancet Diabetes & Endocrinology, 7 Aug 2026
